Company Reports Q1 Revenue of $12.49M, Exceeding Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 9 hours ago
0mins
Should l Buy APYX?
Reports Q1 revenue $12.49M, consensus $10.77M. "Our first quarter results reflect continued execution against our commercial strategy, with strong revenue growth driven by adoption of AYON in the U.S., increasing demand for Renuvion internationally and an increase in handpieces worldwide," said Charlie Goodwin, President and Chief Executive Officer. "During the quarter, our team delivered on several fronts, including growing Surgical Aesthetic sales including expansion of AYON and exceeding expectations in key international markets such as South Korea. Taken together, this performance reinforces our confidence in the business and supports our decision to raise our revenue outlook for the full year 2026."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APYX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APYX
Wall Street analysts forecast APYX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.920
Low
6.00
Averages
7.00
High
8.00
Current: 2.920
Low
6.00
Averages
7.00
High
8.00
About APYX
Apyx Medical, Inc., formerly Apyx Medical Corporation, is a surgical aesthetics company. Its segments include Advanced Energy and Original Equipment Manufacturer (OEM). The Advanced Energy segment’s product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It focuses on the cosmetic surgery market, where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Through OEM agreements, the OEM segment, designs, develops and manufactures electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers as well as start-up businesses in need of its energy-based designs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Apyx Medical Q1 Earnings Exceed Expectations
- Earnings Highlights: Apyx Medical reported a Q1 GAAP EPS of -$0.05, beating expectations by $0.06, with revenue of $12.5 million reflecting a 32.6% year-over-year increase, surpassing forecasts by $1.73 million, indicating strong market performance.
- Upward Revision of 2026 Guidance: The company raised its total revenue guidance for 2026 to a range of $59.0 million to $60.0 million, up from the previous $57.5 million to $58.5 million, reflecting confidence in future growth prospects.
- Segment Revenue Expectations: Surgical Aesthetics revenue is projected between $54.0 million and $55.0 million, an increase from the prior guidance of $53.0 million to $54.0 million, while OEM revenue is expected to be approximately $5.0 million, up from $4.5 million, showcasing robust growth across business lines.
- Cost Control Measures: The company anticipates operating expenses to remain below $45.0 million for 2026, ensuring that it maintains cost control while driving revenue growth, thereby enhancing overall profitability and financial health.
See More
Renuvion Wins Best Minimally Invasive Skin Tightener Award Again
- Award Recognition: Renuvion has been named the 'Best Minimally Invasive Skin Tightener' for the second consecutive year, reflecting its leadership in surgical aesthetics and enhancing trust among physicians and patients, thereby boosting brand recognition in the market.
- Technological Edge: As the only FDA-cleared device for use after liposuction, Renuvion, combined with the AYON platform, improves physician workflow efficiency and treatment customization, further expanding the company's market share in body contouring.
- Industry Trust: A 2024 Wakefield Research survey indicates that 80% of surgeons consider Renuvion the most trusted body contouring technology, a statistic that not only enhances product competitiveness but also lays a foundation for future sales growth.
- Innovation Commitment: Apyx Medical is dedicated to improving patients' lives through its Helium Plasma Platform Technology, with over 90 clinical publications supporting the effectiveness of Renuvion and J-Plasma, further solidifying its leadership position in the cosmetic surgery market.
See More
Renuvion Wins Best Minimally Invasive Skin Tightener Award Again
- Award Recognition: Renuvion has been named the 'Best Minimally Invasive Skin Tightener' for the second consecutive year, reflecting its leadership in surgical aesthetics and enhancing the company's brand influence in the market.
- High Trust Among Surgeons: A 2024 Wakefield Research survey indicates that 80% of surgeons consider Renuvion the most trusted body contouring technology, which not only boosts physician confidence but also increases patient acceptance.
- Technological Innovation: Renuvion is the only FDA-cleared device for use after liposuction, and its integration with the AYON platform enhances procedural efficiency and treatment diversity, driving advancements in minimally invasive surgeries.
- Strong Market Potential: Apyx Medical showcases its competitive strength in the cosmetic surgery market through innovative products like Renuvion and J-Plasma, supported by over 90 clinical publications, which is expected to attract more medical institutions' attention and collaboration.
See More
Apyx Medical Reports Narrower Loss and Revenue Growth
- Improved Financial Performance: Apyx Medical reported a narrower net loss of $1.29 million in Q4 2025, translating to a loss of $0.03 per share, a significant improvement from $4.63 million and $0.12 per share in the previous year, indicating enhanced financial health.
- Significant Revenue Growth: Total revenue surged 34.7% to $19.16 million, primarily driven by a 36% increase in surgical aesthetics sales, particularly bolstered by the strong performance of the AYON product since its commercial launch in September 2025, which further propelled overall results.
- Optimistic 2026 Outlook: The company raised its 2026 revenue guidance to between $57.5 million and $58.5 million, reflecting an 8% to 10% increase from $52.8 million in 2025, showcasing confidence in future market demand.
- Strong Cash Position: As of December 31, 2025, Apyx Medical had cash and cash equivalents of $31.74 million, and with stringent cost controls and effective working capital management, the company expects its cash runway to extend through 2027, enhancing financial stability.
See More
Apyx Medical Reports Q4 2025 Earnings Highlights
- Significant Revenue Growth: Apyx Medical reported a revenue of $19.2 million for Q4 2025, a 35% increase from $14.2 million in Q4 2024, indicating strong performance amid robust market demand.
- Strong Surgical Aesthetics Performance: The surgical aesthetics segment generated $16.7 million, reflecting a 38% year-over-year increase, primarily driven by the successful launch of the Aon body contouring system, showcasing the company's competitive edge in this market.
- Reduced Net Loss: Despite revenue growth, Apyx reported a net loss of $1.3 million for Q4, significantly improved from a loss of $4.6 million in the same quarter last year, highlighting effective cost control and operational efficiency.
- Optimistic 2026 Outlook: The company anticipates total revenue guidance of $57.5 million to $58.5 million for 2026, representing a 9% to 11% increase from 2025, with the surgical aesthetics segment expected to grow by 17% to 19%, reflecting confidence in future growth prospects.
See More
Apyx Medical Reports Record Q4 2025 Revenue Driven by AYON Launch
- Record Revenue: Apyx Medical reported a record revenue of $19.2 million for Q4 2025, a 35% increase year-over-year, with surgical aesthetics product sales rising 38% to $16.7 million, primarily driven by the successful launch of the AYON body contouring system, indicating strong performance in the rapidly growing surgical aesthetics market.
- AYON System Innovation: The AYON system integrates fat removal, closed-loop contouring, tissue contraction, and electrosurgical capabilities, designed to address many challenges of existing systems, and is expected to further solidify its position as the first fully integrated body contouring system, with a 510(k) application for expanded functionality anticipated.
- Optimistic Market Outlook: The company expects total revenue for fiscal year 2026 to range between $57.5 million and $58.5 million, representing a 9% to 11% increase, with surgical aesthetics segment revenue guidance set at $53 million to $54 million, reflecting a continued focus and resource allocation to this segment.
- Cost Control and Cash Flow: Operating expenses remained flat at $12 million, while Apyx Medical achieved an adjusted EBITDA of $0.7 million, with cash and cash equivalents standing at $31.7 million, projected to last through 2027, indicating a commitment to maintaining financial health while actively positioning for future growth.
See More
Apyx Medical Q1 Earnings Exceed Expectations
- Earnings Highlights: Apyx Medical reported a Q1 GAAP EPS of -$0.05, beating expectations by $0.06, with revenue of $12.5 million reflecting a 32.6% year-over-year increase, surpassing forecasts by $1.73 million, indicating strong market performance.
- Upward Revision of 2026 Guidance: The company raised its total revenue guidance for 2026 to a range of $59.0 million to $60.0 million, up from the previous $57.5 million to $58.5 million, reflecting confidence in future growth prospects.
- Segment Revenue Expectations: Surgical Aesthetics revenue is projected between $54.0 million and $55.0 million, an increase from the prior guidance of $53.0 million to $54.0 million, while OEM revenue is expected to be approximately $5.0 million, up from $4.5 million, showcasing robust growth across business lines.
- Cost Control Measures: The company anticipates operating expenses to remain below $45.0 million for 2026, ensuring that it maintains cost control while driving revenue growth, thereby enhancing overall profitability and financial health.
See More
Renuvion Wins Best Minimally Invasive Skin Tightener Award Again
- Award Recognition: Renuvion has been named the 'Best Minimally Invasive Skin Tightener' for the second consecutive year, reflecting its leadership in surgical aesthetics and enhancing trust among physicians and patients, thereby boosting brand recognition in the market.
- Technological Edge: As the only FDA-cleared device for use after liposuction, Renuvion, combined with the AYON platform, improves physician workflow efficiency and treatment customization, further expanding the company's market share in body contouring.
- Industry Trust: A 2024 Wakefield Research survey indicates that 80% of surgeons consider Renuvion the most trusted body contouring technology, a statistic that not only enhances product competitiveness but also lays a foundation for future sales growth.
- Innovation Commitment: Apyx Medical is dedicated to improving patients' lives through its Helium Plasma Platform Technology, with over 90 clinical publications supporting the effectiveness of Renuvion and J-Plasma, further solidifying its leadership position in the cosmetic surgery market.
See More
Renuvion Wins Best Minimally Invasive Skin Tightener Award Again
- Award Recognition: Renuvion has been named the 'Best Minimally Invasive Skin Tightener' for the second consecutive year, reflecting its leadership in surgical aesthetics and enhancing the company's brand influence in the market.
- High Trust Among Surgeons: A 2024 Wakefield Research survey indicates that 80% of surgeons consider Renuvion the most trusted body contouring technology, which not only boosts physician confidence but also increases patient acceptance.
- Technological Innovation: Renuvion is the only FDA-cleared device for use after liposuction, and its integration with the AYON platform enhances procedural efficiency and treatment diversity, driving advancements in minimally invasive surgeries.
- Strong Market Potential: Apyx Medical showcases its competitive strength in the cosmetic surgery market through innovative products like Renuvion and J-Plasma, supported by over 90 clinical publications, which is expected to attract more medical institutions' attention and collaboration.
See More
Apyx Medical Reports Narrower Loss and Revenue Growth
- Improved Financial Performance: Apyx Medical reported a narrower net loss of $1.29 million in Q4 2025, translating to a loss of $0.03 per share, a significant improvement from $4.63 million and $0.12 per share in the previous year, indicating enhanced financial health.
- Significant Revenue Growth: Total revenue surged 34.7% to $19.16 million, primarily driven by a 36% increase in surgical aesthetics sales, particularly bolstered by the strong performance of the AYON product since its commercial launch in September 2025, which further propelled overall results.
- Optimistic 2026 Outlook: The company raised its 2026 revenue guidance to between $57.5 million and $58.5 million, reflecting an 8% to 10% increase from $52.8 million in 2025, showcasing confidence in future market demand.
- Strong Cash Position: As of December 31, 2025, Apyx Medical had cash and cash equivalents of $31.74 million, and with stringent cost controls and effective working capital management, the company expects its cash runway to extend through 2027, enhancing financial stability.
See More
Apyx Medical Reports Q4 2025 Earnings Highlights
- Significant Revenue Growth: Apyx Medical reported a revenue of $19.2 million for Q4 2025, a 35% increase from $14.2 million in Q4 2024, indicating strong performance amid robust market demand.
- Strong Surgical Aesthetics Performance: The surgical aesthetics segment generated $16.7 million, reflecting a 38% year-over-year increase, primarily driven by the successful launch of the Aon body contouring system, showcasing the company's competitive edge in this market.
- Reduced Net Loss: Despite revenue growth, Apyx reported a net loss of $1.3 million for Q4, significantly improved from a loss of $4.6 million in the same quarter last year, highlighting effective cost control and operational efficiency.
- Optimistic 2026 Outlook: The company anticipates total revenue guidance of $57.5 million to $58.5 million for 2026, representing a 9% to 11% increase from 2025, with the surgical aesthetics segment expected to grow by 17% to 19%, reflecting confidence in future growth prospects.
See More
Apyx Medical Reports Record Q4 2025 Revenue Driven by AYON Launch
- Record Revenue: Apyx Medical reported a record revenue of $19.2 million for Q4 2025, a 35% increase year-over-year, with surgical aesthetics product sales rising 38% to $16.7 million, primarily driven by the successful launch of the AYON body contouring system, indicating strong performance in the rapidly growing surgical aesthetics market.
- AYON System Innovation: The AYON system integrates fat removal, closed-loop contouring, tissue contraction, and electrosurgical capabilities, designed to address many challenges of existing systems, and is expected to further solidify its position as the first fully integrated body contouring system, with a 510(k) application for expanded functionality anticipated.
- Optimistic Market Outlook: The company expects total revenue for fiscal year 2026 to range between $57.5 million and $58.5 million, representing a 9% to 11% increase, with surgical aesthetics segment revenue guidance set at $53 million to $54 million, reflecting a continued focus and resource allocation to this segment.
- Cost Control and Cash Flow: Operating expenses remained flat at $12 million, while Apyx Medical achieved an adjusted EBITDA of $0.7 million, with cash and cash equivalents standing at $31.7 million, projected to last through 2027, indicating a commitment to maintaining financial health while actively positioning for future growth.
See More
